Background: In the double-blind, phase 3 KEYNOTE-189 study (NCT02578680), pembrolizumab+pemetrexed/platinum significantly improved OS and PFS over placebo+pemetrexed/platinum as first-line therapy for nonsquamous NSCLC. Overall, the incidence and severity of AEs with pembrolizumab+pemetrexed/platinum was similar to those with placebo+pemetrexed/platinum. We report the prespecified patient-reported outcome (PRO) analyses from KEYNOTE-189. Method: 616 patients were randomized to pembrolizumab 200 mg Q3W or placebo for 2 years; all patients received pemetrexed plus 4 cycles of carboplatin/cisplatin. EORTC QLQ-C30 and QLQ-LC13 were administered at cycles 1-5, then every 3 cycles during year 1, and every 4 cycles during years 2/3. Key PROs were change from baseline to weeks 12 and 21 in the QLQ-C30 global health status (GHS)/quality of life (QoL) score and time to deterioration in composite of cough/chest pain/ dyspnea. PROs were analyzed in all treated patients who completed 1 PRO instrument (n ¼ 602). P values are nominal and 2-sided. Results: QLQ-C30 compliance was w90% at baseline and week 12 in both arms and was w76% with pembrolizumab and w64% with placebo at week 21. Mean baseline scores were 61.98 and 60.56 in the pembrolizumab and placebo arms, respectively. At weeks 12 and 21, GHS/QoL scores were stable with pembrolizumab and decreased with placebo, with significantly greater decrement with placebo at week 21 (Table) . The proportion of improved GHS/QoL was similar at week 12 (28.9% with pembrolizumab vs 26.5% with placebo) but was greater with pembrolizumab at week 21 (30.1% vs 22.5%). Median time to deterioration in composite of cough/chest pain/dyspnea was not reached (NR) with pembrolizumab (95% CI, 10.2 months-NR) vs 7.0 months (95% CI, 4.8-NR) with placebo (HR, 0.81; 95% CI, 0.60-1.09; P¼0.161). Conclusion: In KEYNOTE-189, pembrolizumab+pemetrexed/platinum maintained or improved health-related QoL over placebo+pemetrexed/ platinum. These data support use of pembrolizumab+pemetrexed/ platinum as first-line therapy for metastatic nonsquamous NSCLC.
Cross Cancer Institute, University of Alberta, Edmonton, AB/CA, 6 Department of Thoracic Oncology, Aichi Cancer Center, Nagoya/JP, 7 Merck & Co., Inc., Kenilworth, NJ/US Background: PD-L1 expression on tumor cells is associated with improved clinical benefit from immunotherapies targeting the PD-1 pathway. We conducted a global, multicenter, retrospective observational study to determine real-world prevalence of tumor PD-L1 expression in patients with advanced NSCLC. Method: Patients 18 years with histologically confirmed stage IIIB/IV NSCLC and a tumor tissue block (5 years old) obtained before treatment at or after this stage were identified in 45 centers across 18 countries including 4 centers in Argentina and Colombia. PD-L1 tumor expression was evaluated at each institution using the PD-L1 IHC 22C3 pharmDx kit (Agilent, Santa Clara, CA, USA). The percentages of patients with PD-L1 tumor proportion score (TPS) 50%, TPS 1%, and TPS <1% were described overall and by relevant clinicopathologic characteristics. Results: Of 2617 patients who met inclusion criteria, 2368 (90%) had PD-L1 data (of which 266 were from Argentina and Colombia sites); 530 (22%) were TPS 50%, 1232 (52%) were TPS 1%, and 1136 (48%) were TPS <1% (Table) . The percentage of patients with PD-L1 TPS 50% and TPS 1%, respectively were: 22%/52% in Europe; 22%/53% in Asia Pacific; 21%/47% in the Americas, and 24%/55% in other countries. The prevalence of EGFR mutations (19%) and ALK alterations (3%) was consistent with prior reports in metastatic NSCLC. Among 1064 patients negative for both EGFR mutation and ALK alteration, the percentage of patients with PD-L1 TPS 50% and TPS 1%, respectively, were 27% and 53%. Conclusion: This is the largest real-world study in advanced NSCLC to date evaluating PD-L1 tumor expression using the 22C3 pharmDx kit. Testing failure rate was low despite local evaluation of PD-L1 TPS across a large number of sites. Prevalence of PD-L1 TPS 50% and TPS 1% was similar across geographic regions and broadly consistent with central testing results from clinical trial screening populations. Ensartinib has demonstrated marked efficacy and safety in patients with advanced NSCLC who are ALK tyrosine kinase inhibitor (TKI) naïve and crizotinib resistant and has intracranial activity in the central nervous system (CNS). We report updated data. Method: In this ongoing phase I/II study, patients (pts) with advanced ALK positive NSCLC and measurable disease were given ensartinib 225mg once daily (QD) on a continuous 28-day schedule (NCT01625234). Patients who were either ALK TKI-naïve or had received prior crizotinib and no other ALK TKI received ensartinib until disease progression (PD), unacceptable toxicity or investigator discretion. Patients with asymptomatic brain metastases were allowed to enroll. All pts were assessed for adverse events (AEs) using CTCAE version 4.03, and response was assessed locally every 8 weeks using RECIST 1.1. Results: As of the June 01, 2018 data cutoff, 52 ALK evaluable pts (ALK+ NSCLC pts at 200mg QD with a post baseline response assessment) were assessed (26 male/26 female; median age of 54 (20-80) years; 56% with an ECOG PS of 1). The most common drug-related AEs included rash (54%), nausea (35%), pruritus (31%), vomiting (25%), and fatigue (24%). Most AEs were Grade (G) 1-2. The G3 treatment-related AEs were rash (14%), pruritus (6%), fatigue (3%), decreased appetite (2%), nausea (1%), vomiting (1%), edema (1%), and AST increase (1%). Overall, complete response (CR) or partial response (PR) was achieved in 37 pts, a response rate (RR) of 71%, and 12 pts had stable disease (SD), resulting in a disease control rate (DCR) of 94%. Of the 15 ALK TKI-naïve patients, responses were observed in 12 pts (RR 80%) and 1 had SD, resulting in a DCR of 87%. Interestingly, the 2 pts with PD were ALK FISH-positive via local testing, but negative when analyzed using NGS. In the 37 pts with prior crizotinib but no other ALK TKI, 25 pts responded (1 CR/24 PR) and 1 had SD, resulting in a DCR of 97%. Intracranial responses were observed in 3/3 ALK TKI-naïve pts with target brain lesions at baseline (including 1 CR) and 7/13 crizotinib resistant pts with target lesions at baseline (including 2 CR), resulting in an overall intracranial DCR of 100%. Conclusion: Ensartinib is welltolerated and induces responses in both ALK TKI-naive and crizotinib resistant ALK+ NSCLC pts, as well as patients with CNS lesions. Enrollment in this study and a global phase III study of ensartinib is ongoing. Instituto Nacional Del Torax, Ministerio de Salud, Santiago/CL, 4 Centro de Investigación Clínica Bradford Hill, Santiago/CL Background: Advances in precision medicine, which treats patients with therapies directed against the specific molecular alterations driving their cancers, have transformed oncology. This approach requires identification of the molecular alterations generating the cancer, the development of targeted therapies, and the validation of companion diagnostics assays to identify patient populations for clinical trials and eventual implementation. In developed countries from North America and Europe, the landscape of the actionable genomic alterations is well known. Thanks to global efforts, such as TCGA or ICGC, today it is possible to establish that a set oncogenic actionable driver mutations (including rearrangement and relevant mutation from KRAS, EGFR, ALK, ERBB2, BRAF, PIK3CA, MET, NRAS, MEK and AKT1) is found in about a 64% of lung adenocarcinomas patients. However, there is still very little information about the molecular epidemiology of lung cancer actionable genes in Latin American patients. Method: The general aims of NIRVANA study (NCT03220230) are the validation of more sensitive and high-throughput technologies for the study of non-small cell lung cancer (NSCLC) genomics alterations, and the generation of a comprehensive, high quality, clinical, pathological, and genomics data of NSCLC in Chile, Brazil and Peru. So far, mutation prevalence of 52 genes (Oncomine Focus Assay, Thermo Fisher Scientific) were analyzed in 1253 NSCLC tumor samples from the NIRVANA Chilean patients. After the variant calling and quality filtering process, potential somatic mutations were annotated against COSMIC, dbSNP and ExAC to classify them as known or novel variants. SIFT and PolyPhen were used to assess the functional impact of the variants. Prevalence is reported within 95% CI of the gene and mutation type level (hotspot or gene fusions). Results: The prevalence of genomic alterations in the 52 genes is similar to previous studies. For example, ALK fusions were present in 3.83% (CI 2.74% -5.32%) of the tumors. Among the 973 DNA variants with a deleterious effect, 63% of them corresponded to novel variants that could be of clinical interest. Compared to the default variant calling process of known variants, this strategy increases by approximately 5-times the potential of finding new mutations for further analyses and new therapeutic opportunities. Conclusion: This work constitutes one of the first approaches towards a comprehensive understanding of NSCLC genomic and actionable mutations in Chilean patients. Keywords: Somatic mutations, NIRVANA, Precision Medicine, NSCLC
